A citation-based method for searching scientific literature

Luis Miguel Ruilope, Andrej Dukat, Michael Böhm, Yves Lacourcière, Jianjian Gong, Martin P Lefkowitz. Lancet 2010
Times Cited: 380







List of co-cited articles
2145 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
70

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong,[...]. Lancet 2012
726
35

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
Kazuomi Kario, Ningling Sun, Fu-Tien Chiang, Ouppatham Supasyndh, Sang Hong Baek, Akiko Inubushi-Molessa, Ying Zhang, Hiromi Gotou, Martin Lefkowitz, Jack Zhang. Hypertension 2014
142
33

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Scott D Solomon, John J V McMurray, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske,[...]. N Engl J Med 2019
724
31

Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Bryan Williams, John R Cockcroft, Kazuomi Kario, Dion H Zappe, Patrick C Brunel, Qian Wang, Weinong Guo. Hypertension 2017
104
29

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague, Ricardo Rocha, Eugene Braunwald. N Engl J Med 2019
452
26

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Jessie Gu, Adele Noe, Priya Chandra, Suliman Al-Fayoumi, Monica Ligueros-Saylan, Ramesh Sarangapani, Suzanne Maahs, Gary Ksander, Dean F Rigel, Arco Y Jeng,[...]. J Clin Pharmacol 2010
330
25

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Roland E Schmieder, Frank Wagner, Michael Mayr, Christian Delles, Christian Ott, Christian Keicher, Maja Hrabak-Paar, Tobias Heye, Solveig Aichner, Yasser Khder,[...]. Eur Heart J 2017
65
30

Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Tzung-Dau Wang, Ru-San Tan, Hae-Young Lee, Sang-Hyun Ihm, Moo-Yong Rhee, Brian Tomlinson, Parasar Pal, Fan Yang, Elizabeth Hirschhorn, Margaret F Prescott,[...]. Hypertension 2017
61
31

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Milton Packer, John J V McMurray, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. Circulation 2015
423
18

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Milton Packer, Robert M Califf, Marvin A Konstam, Henry Krum, John J McMurray, Jean-Lucien Rouleau, Karl Swedberg. Circulation 2002
470
18

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
John B Kostis, Milton Packer, Henry R Black, Roland Schmieder, David Henry, Elliott Levy. Am J Hypertens 2004
365
18

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Akshay S Desai, Scott D Solomon, Amil M Shah, Brian L Claggett, James C Fang, Joseph Izzo, Kevin McCague, Cheryl A Abbas, Ricardo Rocha, Gary F Mitchell. JAMA 2019
120
18

Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
Ouppatham Supasyndh, Jian'an Wang, Kudsia Hafeez, Ying Zhang, Jack Zhang, Hiromi Rakugi. Am J Hypertens 2017
28
60

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
17

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Jelena P Seferovic, Brian Claggett, Sara B Seidelmann, Ellen W Seely, Milton Packer, Michael R Zile, Jean L Rouleau, Karl Swedberg, Martin Lefkowitz, Victor C Shi,[...]. Lancet Diabetes Endocrinol 2017
152
15

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Richard Haynes, Parminder K Judge, Natalie Staplin, William G Herrington, Benjamin C Storey, Angelyn Bethel, Louise Bowman, Nigel Brunskill, Paul Cockwell, Michael Hill,[...]. Circulation 2018
78
19

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Michael Böhm, Robin Young, Pardeep S Jhund, Scott D Solomon, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Karl Swedberg,[...]. Eur Heart J 2017
101
14

Long-term neprilysin inhibition - implications for ARNIs.
Duncan J Campbell. Nat Rev Cardiol 2017
79
17


Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
Deanna G Cheung, Diego Aizenberg, Vladimir Gorbunov, Kudsia Hafeez, Chien-Wei Chen, Jack Zhang. J Clin Hypertens (Greenwich) 2018
24
54

2018 ESC/ESH Guidelines for the management of arterial hypertension.
Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, Michel Burnier, Denis L Clement, Antonio Coca, Giovanni de Simone, Anna Dominiczak,[...]. Eur Heart J 2018
13

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
Sadayoshi Ito, Minoru Satoh, Yuko Tamaki, Hiromi Gotou, Alan Charney, Naoko Okino, Mizuki Akahori, Jack Zhang. Hypertens Res 2015
56
23

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
John J V McMurray, Alice M Jackson, Carolyn S P Lam, Margaret M Redfield, Inder S Anand, Junbo Ge, Marty P Lefkowitz, Aldo P Maggioni, Felipe Martinez, Milton Packer,[...]. Circulation 2020
127
13

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
James L Januzzi, Margaret F Prescott, Javed Butler, G Michael Felker, Alan S Maisel, Kevin McCague, Alexander Camacho, Ileana L Piña, Ricardo A Rocha, Amil M Shah,[...]. JAMA 2019
205
13

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
13

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
12


Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension.
J Jordan, R Stinkens, T Jax, S Engeli, E E Blaak, M May, B Havekes, C Schindler, D Albrecht, P Pal,[...]. Clin Pharmacol Ther 2017
60
18

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
Chirag Bavishi, Franz H Messerli, Bernard Kadosh, Luis M Ruilope, Kazuomi Kario. Eur Heart J 2015
58
18

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg,[...]. JACC Heart Fail 2018
142
11


LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.
Kazuomi Kario, Yuko Tamaki, Naoko Okino, Hiromi Gotou, Min Zhu, Jack Zhang. J Clin Hypertens (Greenwich) 2016
29
37

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, Milton Packer, Michael Zile, Karl Swedberg, Jean Rouleau, Marc A Pfeffer, Akshay Desai, Lars H Lund,[...]. Circulation 2020
153
11

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
11

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Thomas H Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula, Parasar Pal, Marie-Anne Valentin, Markus Hinder, Stanford Jhee, Hakop Gevorkyan, Iris Rajman. Br J Clin Pharmacol 2016
69
14

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Adriaan A Voors, Mauro Gori, Licette C Y Liu, Brian Claggett, Michael R Zile, Burkert Pieske, John J V McMurray, Milton Packer, Victor Shi, Martin P Lefkowitz,[...]. Eur J Heart Fail 2015
123
10



Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Bryan Williams, Thomas M MacDonald, Steve Morant, David J Webb, Peter Sever, Gordon McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Jackie Salsbury,[...]. Lancet 2015
562
10

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Paul W Armstrong, Burkert Pieske, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Javed Butler, Carolyn S P Lam, Piotr Ponikowski, Adriaan A Voors, Gang Jia,[...]. N Engl J Med 2020
320
10


Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Scott D Solomon, Adel R Rizkala, Jianjian Gong, Wenyan Wang, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer,[...]. JACC Heart Fail 2017
172
9

Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
Ouppatham Supasyndh, Ningling Sun, Kazuomi Kario, Kudsia Hafeez, Jack Zhang. Hypertens Res 2017
21
42

Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Thomas G von Lueder, Bing H Wang, Andrew R Kompa, Li Huang, Randy Webb, Pierre Jordaan, Dan Atar, Henry Krum. Circ Heart Fail 2015
182
9

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
J L Rouleau, M A Pfeffer, D J Stewart, D Isaac, F Sestier, E K Kerut, C B Porter, G Proulx, C Qian, A J Block. Lancet 2000
322
9

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Monica M Colvin, Mark H Drazner, Gerasimos S Filippatos, Gregg C Fonarow, Michael M Givertz,[...]. Circulation 2017
9

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Paul K Whelton, Robert M Carey, Wilbert S Aronow, Donald E Casey, Karen J Collins, Cheryl Dennison Himmelfarb, Sondra M DePalma, Samuel Gidding, Kenneth A Jamerson, Daniel W Jones,[...]. J Am Coll Cardiol 2018
9

Spironolactone for heart failure with preserved ejection fraction.
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, Robin Boineau, Inder S Anand, Brian Claggett, Nadine Clausell, Akshay S Desai, Rafael Diaz, Jerome L Fleg,[...]. N Engl J Med 2014
9

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Salim Yusuf, Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John J V McMurray, Eric L Michelson, Bertil Olofsson, Jan Ostergren. Lancet 2003
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.